Zavegepant nasal spray effectively treats acute migraine across triptan-naïve, insufficient, and current users
Background
Acute migraine treatment often relies on triptans, but many patients experience insufficient response or have contraindications. This creates a significant treatment gap. Calcitonin gene-related peptide (CGRP) receptor antagonists, known as gepants, offer a novel mechanism by blocking CGRP, a key neuropeptide in migraine pathophysiology. Zavegepant, a third-generation intranasal gepant, provides a non-oral option, making it particularly appealing for patients with nausea or difficulty swallowing during an attack. Understanding its efficacy across different triptan experience levels is crucial for optimizing patient selection.
Study Design
Researchers conducted post hoc analyses of pooled efficacy data from two double-blind, single-dose, randomized, placebo-controlled trials (NCT03872453, NCT04571060) and safety data from a 1-year, multiple-dose, open-label study (NCT04408794). Adult participants with acute migraine were treated with zavegepant 10 mg nasal spray or placebo. Efficacy endpoints were pain freedom (2h PF) and most bothersome symptom (2h MBS) freedom at 2 hours post-dose. Participants were categorized by baseline triptan experience: triptan-naïve, triptan insufficient responders (TIR), and current triptan users. Safety assessments included adverse events (AEs).
Results
Pooled efficacy analyses included 2061 participants, while 603 were in the long-term safety analysis. Zavegepant consistently demonstrated superior efficacy over placebo across all triptan experience subgroups for both co-primary endpoints. For 2-hour pain freedom (PF), rates for zavegepant vs. placebo were: current triptan users 21.0% vs. 11.9% (p=0.0254); triptan-naïve 24.8% vs. 17.4% (p=0.0029); and triptan insufficient responders (TIR) 21.8% vs. 12.6% (p=0.0024). For 2-hour most bothersome symptom (MBS) freedom, corresponding rates were: current triptan users 40.0% vs. 29.5% (p=0.0440); triptan-naïve 40.4% vs. 34.0% (p=0.0303); and TIR 41.0% vs. 29.9% (p=0.0035).
Key Findings
- Zavegepant 10 mg nasal spray achieved 2h pain freedom in 21.0% of current triptan users vs. 11.9% for placebo (p=0.0254).
- Triptan-naïve patients experienced 2h pain freedom at 24.8% with zavegepant vs. 17.4% with placebo (p=0.0029).
- Triptan insufficient responders (TIR) achieved 2h pain freedom at 21.8% with zavegepant vs. 12.6% with placebo (p=0.0024).
- Zavegepant provided 2h most bothersome symptom freedom in 41.0% of TIR patients vs. 29.9% for placebo (p=0.0035).
- Safety profiles, including AEs and discontinuations, were consistent across all triptan experience subgroups.
Why It Matters
This analysis confirms that zavegepant 10 mg nasal spray is an effective acute treatment for migraine across a broad patient population, including those who have not responded well to triptans or have never used them. This is a significant finding for clinicians and patients, as it expands the available options, particularly for the challenging-to-treat triptan-insufficient responder group. The consistent efficacy and safety profile across subgroups mean that zavegepant can be considered a first-line or alternative option without needing to factor in prior triptan experience. The established nasal spray route offers a convenient and rapid-acting protocol, especially beneficial during migraine attacks where oral intake might be difficult.
zavegepant
migraine
cgrp-antagonist
acute-treatment
triptan-insufficient
clinical-trial